These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23629495)

  • 1. Trial watch: Sepsis study failure highlights need for trial design rethink.
    Tse MT
    Nat Rev Drug Discov; 2013 May; 12(5):334. PubMed ID: 23629495
    [No Abstract]   [Full Text] [Related]  

  • 2. The search for effective therapy for sepsis: back to the drawing board?
    Angus DC
    JAMA; 2011 Dec; 306(23):2614-5. PubMed ID: 22187284
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of myocardial dysfunction in sepsis: the Toll-like receptor antagonist approach.
    Kimmoun A; Levy B
    Shock; 2011 Dec; 36(6):633-4. PubMed ID: 22089128
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting myeloid differentiation 2 for treatment of sepsis.
    Duan G; Zhu J; Xu J; Liu Y
    Front Biosci (Landmark Ed); 2014 Jun; 19(6):904-15. PubMed ID: 24896325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.
    Barochia A; Solomon S; Cui X; Natanson C; Eichacker PQ
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):479-94. PubMed ID: 21323610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor 4 modulation as a strategy to treat sepsis.
    Wittebole X; Castanares-Zapatero D; Laterre PF
    Mediators Inflamm; 2010; 2010():568396. PubMed ID: 20396414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo Toll-like receptor 4 antagonism restores cardiac function during endotoxemia.
    Ehrentraut S; Lohner R; Schwederski M; Ehrentraut H; Boehm O; Noga S; Langhoff P; Baumgarten G; Meyer R; Knuefermann P
    Shock; 2011 Dec; 36(6):613-20. PubMed ID: 22089127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
    Opal SM; Laterre PF; Francois B; LaRosa SP; Angus DC; Mira JP; Wittebole X; Dugernier T; Perrotin D; Tidswell M; Jauregui L; Krell K; Pachl J; Takahashi T; Peckelsen C; Cordasco E; Chang CS; Oeyen S; Aikawa N; Maruyama T; Schein R; Kalil AC; Van Nuffelen M; Lynn M; Rossignol DP; Gogate J; Roberts MB; Wheeler JL; Vincent JL;
    JAMA; 2013 Mar; 309(11):1154-62. PubMed ID: 23512062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.
    Tidswell M; LaRosa SP
    Expert Rev Anti Infect Ther; 2011 May; 9(5):507-20. PubMed ID: 21609262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of lipopolysaccharide-induced blood pressure attenuation and vascular contractility.
    Ehrentraut S; Frede S; Stapel H; Mengden T; Grohé C; Fandrey J; Meyer R; Baumgarten G
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2170-6. PubMed ID: 17656666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Toll-like receptors, a new way of treatment?].
    Pedersen CV; Østergaard LJ; Mogensen TH; Paludan SR; Bertelsen LS
    Ugeskr Laeger; 2007 Jun; 169(23):2193-8. PubMed ID: 17592684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis.
    Kalil AC; LaRosa SP; Gogate J; Lynn M; Opal SM;
    Shock; 2011 Oct; 36(4):327-31. PubMed ID: 21701421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the pathogenesis and therapy of sepsis and septic shock.
    Llewelyn M; Cohen J
    Curr Clin Top Infect Dis; 2001; 21():148-71. PubMed ID: 11572150
    [No Abstract]   [Full Text] [Related]  

  • 14. The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy.
    Ehrentraut H; Weber C; Ehrentraut S; Schwederski M; Boehm O; Knuefermann P; Meyer R; Baumgarten G
    Eur J Heart Fail; 2011 Jun; 13(6):602-10. PubMed ID: 21613426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury.
    Shimamoto A; Chong AJ; Yada M; Shomura S; Takayama H; Fleisig AJ; Agnew ML; Hampton CR; Rothnie CL; Spring DJ; Pohlman TH; Shimpo H; Verrier ED
    Circulation; 2006 Jul; 114(1 Suppl):I270-4. PubMed ID: 16820585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials.
    Yende S; Austin S; Rhodes A; Finfer S; Opal S; Thompson T; Bozza FA; LaRosa SP; Ranieri VM; Angus DC
    Crit Care Med; 2016 Aug; 44(8):1461-7. PubMed ID: 26992066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TLR4 antagonist Eritoran protects mice from lethal influenza infection.
    Shirey KA; Lai W; Scott AJ; Lipsky M; Mistry P; Pletneva LM; Karp CL; McAlees J; Gioannini TL; Weiss J; Chen WH; Ernst RK; Rossignol DP; Gusovsky F; Blanco JC; Vogel SN
    Nature; 2013 May; 497(7450):498-502. PubMed ID: 23636320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury.
    Liu M; Gu M; Xu D; Lv Q; Zhang W; Wu Y
    Transplant Proc; 2010 Jun; 42(5):1539-44. PubMed ID: 20620471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases.
    Leon CG; Tory R; Jia J; Sivak O; Wasan KM
    Pharm Res; 2008 Aug; 25(8):1751-61. PubMed ID: 18493843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Septic shock: new pharmacotherapy options or better trial design?
    Vincent JL; Van Nuffelen M
    Expert Opin Pharmacother; 2013 Apr; 14(5):561-70. PubMed ID: 23452102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.